首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

2096455

神經調控設備：市場洞察、競爭格局及市場預測 - 2034 年

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034

出版日期: 2026年07月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

神經調控設備市場概述

概述：

到2025年，神經調控設備市場規模達到 64.2億美元，預計到2034年將達到 158.5億美元。該成長的促進因素包括：全球慢性疼痛和神經系統疾病負擔日益加重、封閉回路型和人工智慧驅動的刺激平台迅速普及，以及主要市場法規核准和保險覆蓋範圍的擴大。
全球神經調控設備市場預計在2026年至2034年的預測期內將以 10.6%的CAGR成長。
依設備類型分類，到2025年，脊髓刺激設備細分市場將佔 42%的市場佔有率，推動神經調節設備市場的發展。
依應用領域分類，到2025年，疼痛管理領域將佔市場佔有率的47%，推動神經調節設備市場的發展。
依類型分類，到2025年，侵入式設備將引領神經調節設備市場，佔據 94%的市場佔有率。
依最終用戶分類，到2025年，醫院領域將引領市場，佔神經調節設備市場佔有率的51%。
到2025年，北美將以 44%的銷售額引領全球神經調節設備市場，在全球區域市場佔有率中佔據最高地位。

神經調控裝置是一種可植入或非侵入性的醫療技術，它透過對中樞或周圍神經系統進行靶向電刺激、磁刺激或其他能量刺激來調節神經活動，達到治療效果。由於慢性疼痛、運動障礙、骨盆底功能障礙和神經系統疾病通常難以透過藥物治療得到改善，臨床醫生擴大採用神經調控裝置作為一種持續、無鴉片類藥物且可重新編程的替代療法。這些裝置包括脊髓刺激設備、深部腦部刺激器、薦神經刺激器、薦骨神經刺激器以及一些新興平台，例如迷走神經刺激設備神經刺激設備和背根神經節刺激器。市場依設備類型（主導）、適應症（疼痛管理、尿失禁和糞便失禁、神經系統疾病、呼吸系統疾病及其他適應症）、方法（有創（植入式）和非有創（經皮或體外）系統）以及最終用戶（醫院、專科診所及其他醫療機構）細分。在慢性疼痛和神經系統疾病全球盛行率不斷上升、封閉回路型控制和人工智慧（AI）驅動的刺激技術快速發展以及法規核准和保險覆蓋範圍不斷擴大的推動下，神經調控設備已成為現代疼痛管理和神經醫學的基石。

神經調控設備市場的主要市場促進因素

全球慢性疼痛和術後腰痛症候群的日益普遍，推動了對脊髓刺激療法的持續需求，而 Nevro 的HFX iQ 和 Medtronic 的Inceptiv閉合迴路可充電刺激器等平台的不斷升級，進一步促進了這一需求。
神經系統疾病和運動障礙負擔日益加重，推動了對深部腦部刺激和迷走神經刺激的需求不斷成長。根據帕金森氏症基金會估計，目前美國約有100萬人患有帕金森氏症，預計到2030年，這一數字將達到120萬人。
封閉回路型、自適應和人工智慧驅動的刺激技術的快速發展改善治療效果並擴大其應用範圍。Medtronic公司的BrainSense自適應DBS系統就是一個典型的例子，該系統於2025年2月獲得FDA批准，成為首個用於治療帕金森氏症的封閉回路型神經調控療法。
法規核准範圍的擴大和保險償付支持的改善日益增加患者獲得這些治療的機會。例如，美國食品藥物管理局（FDA）於2025年 9月批准Medtronic的Altaviva 脛神經調節系統用於治療急迫性急性尿失禁；美國醫療保險和醫療補助服務中心（CMS）於2025年 11月將 Rivanova 公司的VNS 療法納入2026 預保門診保險門診門診病人（2026 申請的償付範圍。
積極的策略投資和併購活動鞏固和擴大在神經調控領域的能力。其中包括Boston Scientific以約5.33億美元收購Nalu Medical的協議（於2025年10月宣布），以及Globus Medical以約2.5億美元收購Nevro Corp.的協議（於2025年2月宣布）。
醫師和病患越來越傾向於使用醫療設備進行非藥物治療，以此取代鴉片類藥物治療，再加上政府對神經調控研究的資助增加，使得符合疼痛和神經系統疾病適應症的病患群體不斷擴大。
在技術創新、適應症擴大、疾病負擔加重以及保險償付支持的推動下，預計到2034年，市場將保持強勁的兩位數成長。

推動神經調控設備市場成長的因素

市場促進因素

慢性疼痛和脊椎疾病的盛行率增加

神經調控設備市場最強勁的促進因素是慢性疼痛、脊椎手術後症候群和其他難治性神經病變在全球範圍內的日益普遍。脊髓刺激療法透過發送微弱的電脈衝阻斷疼痛訊號到達大腦，減少患者對鴉片類藥物的長期依賴，並改善保守治療無效患者的生活品質。各製造商不斷在治療的精準性和便利性方面進行差異化競爭。 Nebro 的「HFX iQ」平台採用基於超過 8萬名植入患者的數千萬個資料點訓練的演算法。Medtronic的「Inceptiv」是目前最薄的植入式脊髓刺激設備（SCS）之一，每秒可感知身體對治療的反應 50 次。Abbott的「Proclaim Plus」系統及其「FlexBurst360」療法可涵蓋多達六個不同的疼痛區域。鑑於各國臨床指引中越來越傾向於在增加鴉片類藥物劑量之前進行神經調節，預計到2034年，對脊髓刺激療法的需求將支持市場成長。

神經系統疾病與運動障礙負擔加重

在全球範圍內，神經系統疾病和運動障礙（例如帕金森氏症、原發性顫抖和難治性癲癇）的負擔日益加重，推動了對深部腦部刺激和迷走神經刺激的需求。根據帕金森氏症基金會估計，目前美國約有100萬人患有帕金森氏症，預計到2030年將增加至120萬人。同時，對於不適合接受腦切除手術的難治性癲癇患者，Rivanova公司的迷走神經刺激療法仍是主要的植入式治療選擇。 CORE-VNS試驗被認為是迄今為止規模最大的真實世界神經調控療法癲癇研究，其結果顯示，對於伴有意識障礙的局部運動性癲癇，36個月時癲癇發作次數中位數減少了80%；對於由局部性發作進展為局部強直-陣攣性發作的癲癇，癲癇發作次數中位數減少了95%。隨著接受運動障礙和陣發性疾病治療的人數增加，對深部腦部刺激和迷走神經刺激設備的需求也隨之增加。

市場限制因素

儘管神經調控設備市場發展動力強勁，但仍面臨諸多限制因素。植入式神經調控系統及相關手術需要大量的初始投入，且不同地區的償付政策和資格標準差異顯著，這可能會減緩價格敏感型市場和新興市場的普及速度。許多設備屬於侵入性手術，有感染、導線移位和硬體相關併發症等固有手術風險。電池壽命、有限的MRI相容性以及定期更換設備的需求也增加了長期治療成本。部分地區缺乏接受過設備植入和程式設計訓練的醫生，限制了業務擴張；而針對III類植入式設備的嚴格監管流程也延長了研發和核准週期。包括用於治療憂鬱症、呼吸系統疾病和其他新興疾病的神經調控療法在內的新適應症的保險償付和普及率仍然參差不齊，且行業正朝著少數幾家主要製造商集中的方向發展，導致競爭風險集中。成本、安全、監管、人力資源和保險償付方面的障礙，再加上疾病負擔加重、技術創新以及對非鴉片類藥物的需求等潛在促進因素，減緩成長速度，儘管這些促進因素依然強勁。

區域性說明

北美洲

到2025年，北美佔全球神經調控設備市場收入的44%。美國憑藉其健全的保險償付體系、主要製造商的集中佈局以及完善的臨床研究基礎設施，在該市場佔據主導地位。 FDA對自適應DBS、脛骶神經調控和周邊神經刺激等一系列技術的批准，將進一步鞏固該地區的主導地位。

歐洲

歐洲是規模龐大、技術先進的區域市場，擁有完善的CE認證和國家醫保償付體系、強大的神經外科和疼痛管理中心網路，以及活躍的臨床證據積累。橫跨德國、英國、法國、義大利和西班牙的區域生產和臨床夥伴關係關係，為慢性疼痛和神經系統疾病的診斷評估和長期管理提供了有力支持。

亞太地區

亞太地區是成長最快的地區，這主要得益於中國、日本、印度、韓國和澳洲慢性疼痛和神經系統疾病負擔的日益加重、神經外科和疼痛管理基礎設施的擴建以及醫療保健投資的增加。此外，醫生培訓計畫的普及和保險償付的改善也加速了脊髓刺激和深部腦部刺激技術在該地區的應用。

世界其他地區

包括拉丁美洲、中東和非洲在內的「世界其他地區」代表著新的成長前沿。醫療基礎設施的不斷完善、人們對神經調控作為長期藥物鎮痛替代方案的認知不斷提高，以及神經外科和疼痛管理專科診療服務的逐步改善，都在推動神經調控技術的普及應用。國際夥伴關係也為培訓和技術轉移提供了支持。

神經調控設備市場近期發展趨勢

2026年1月，Boston Scientific推進了先前宣布的對Naroo Medical的收購，擴展了其神經調控產品系列，將用於治療慢性疼痛的周邊神經刺激療法納入其中。策略意義：將Boston Scientific的慢性疼痛產品系列從脊髓刺激療法擴展至周邊神經刺激療法。

2025年11月，LivaNova PLC宣布，美國醫療保險和醫療補助服務中心（CMS）已批准將迷走神經刺激術（VNS）療法升級為「新技術門診支付分類」，自2026年1月起生效。這將提高該療法在醫院的成本效益。策略意義：這將擴大患者接受VNS療法的機會，並鞏固LivaNova PLC在抗藥性癲癇領域的保險償付地位。

常見問題：

問題1：神經調控設備的市場成長率是多少？

預計從2026年到2034年的預測期內，神經調節設備市場將以 10.6%的CAGR成長。

Q2.神經調控設備市場的市場規模有多大？

到2025年，神經調節設備市場價值將達到 64.2億美元，到2034年將達到 158.5億美元。

Q3.哪個地區推動神經調控設備市場的發展？

北美地區慢性疼痛和神經系統疾病的高發生率、完善的保險償付體係以及主要製造商集中於美國等因素，預計主導神經調節設備市場，到2025年將佔全球銷售額的44%。亞太地區預計將成為預測期內成長最快的地區。

第四季：神經調控設備市場的主要促進因素是什麼？

關鍵促進因素包括慢性疼痛和脊椎手術後症候群在全球範圍內的日益普遍、神經系統疾病和運動障礙（包括帕金森氏症和抗藥性癲癇）負擔的加重、封閉回路型和人工智慧驅動的刺激平台的快速發展、監管批准和保險償付支持的擴大，以及領先製造商之間積極的戰略投資和併購活動。

Q5.神經調控設備市場的主要參與者有哪些？

主要公司包括Abbott Laboratories、Smith's Medical、B. Braun Melsungen AG、Baxter International Inc.、Boston Scientific Corp.、LivaNova PLC、Medtronic、Nevro Corp.、Stryker等。

神經調控設備市場：市場促進因素
- 慢性疼痛和脊椎疾病的盛行率增加
- 神經系統疾病與運動障礙負擔加重
- 邁向封閉回路型與人工智慧回應式刺激的技術進步
- 擴大監理核准範圍，並加強對保險覆蓋範圍的支持力道
神經調控設備市場的市場限制與挑戰
- 設備和治療費用高昂
- 手術風險和保險償付差異。
- 法規的複雜性和人力資源的限制。
神經調控設備市場：市場機會
- 擴展閉合迴路與人工智慧賦能平台
- 拓展新興市場與新適應症

第4章影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章監理分析

美國
歐洲
日本
中國

第6章神經調控設備市場的波特五力分析

供應商的議價能力
買方的議價能力
新進入者的威脅
替代品的威脅
競爭公司之間的競爭

第7章神經調控設備市場評估

依設備類型
- 脊髓刺激設備
- 深部腦部刺激器
- 薦骨神經刺激器
- 迷走神經刺激設備
- 其他
依用途
- 疼痛管理
- 尿失禁/糞便失禁
- 神經病變
- 呼吸系統疾病
依類型
- 侵襲型
- 非侵入性
依最終用戶
- 醫院
- 專科診所
依地區
- 北美洲
- 歐洲
- 亞太地區
- 世界其他地區

第8章神經調控設備市場的競爭格局

市場集中度與結構
競爭定位與市場佔有率分析（加值服務）

第9章神經調控設備市場的新創企業資金籌措與投資趨勢

第10章神經調控設備市場：公司概況與產品概況

Abbott Laboratories
- 公司簡介
- 公司簡介
- 財務概覽
- 服務組合
- 策略舉措/熵
Smith's Medical
- 產品系列
B. Braun Melsungen AG
Baxter International Inc.
Boston Scientific Corp
LivaNova PLC.
Medtronic
Nevro Corp.
Stryker
Omron Corporation

第11章 KOL的觀點

第12章專案方法

第13章關於 DelveInsight

第14章免責聲明與聯絡方式

簡介目錄圖表

Product Code: DIMDCL0029

Neuromodulation Devices Market Summary

Overview:

The Neuromodulation Devices market is estimated at USD 6.42 billion in 2025 and is projected to reach USD 15.85 billion by 2034. Growth is anchored in the rising global burden of chronic pain and neurological disorders, rapid adoption of closed-loop and AI-enabled stimulation platforms, and expanding regulatory approvals and reimbursement across major markets.
The global Neuromodulation Devices market is growing at a CAGR of 10.6% during the forecast period from 2026 to 2034.
By device type, the spinal cord stimulators segment dominated the neuromodulation devices market with a 42% share in 2025.
By application, the pain management segment dominated the neuromodulation devices market with a 47% share in 2025.
By type, the invasive segment dominated the neuromodulation devices market with a 94% share in 2025.
By end-users, the hospitals segment dominated the neuromodulation devices market with a 51% share in 2025.
North America dominated the global neuromodulation devices market revenue with a 44% share in 2025, representing the highest regional market share globally.

A neuromodulation device is a medical technology, implantable or non-invasive, that delivers targeted electrical, magnetic, or other energy-based stimulation to the central or peripheral nervous system to modulate nerve activity for therapeutic benefit. Because chronic pain, movement disorders, and pelvic-floor and neurological conditions often prove refractory to pharmacological therapy, clinicians increasingly turn to device-based neuromodulation as a durable, non-opioid, and reprogrammable alternative. These devices span spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and other emerging platforms such as peripheral nerve and dorsal root ganglion stimulators. The market is organized by device type, led by spinal cord stimulation for chronic pain and failed back surgery syndrome; by application across pain management, urinary and faecal incontinence, neurological disorders, respiratory disorders, and other indications; by type across invasive (implantable) and non-invasive (transcutaneous or external) systems; and by end-user across hospitals, specialty clinics, and other care settings. Driven by the rising global prevalence of chronic pain and neurological disorders, rapid technological progress toward closed-loop and artificial-intelligence-enabled stimulation, and expanding regulatory approvals and reimbursement, neuromodulation devices have become an established pillar of modern pain management and neurological care.

Neuromodulation Devices Market Key Growth Drivers

The rising global prevalence of chronic pain and failed back surgery syndrome is driving durable demand for spinal cord stimulation, reinforced by continued platform upgrades such as Nevro's HFX iQ and Medtronic's Inceptiv closed-loop rechargeable stimulator.
The growing burden of neurological and movement disorders is expanding demand for deep brain and vagus nerve stimulation; the Parkinson's Foundation estimates around 1 million people are living with Parkinson's disease in the U.S., a figure projected to reach 1.2 million by 2030.
Rapid technological advancement toward closed-loop, adaptive, and AI-enabled stimulation is improving outcomes and broadening adoption, exemplified by Medtronic's BrainSense Adaptive DBS system, which received FDA approval in February 2025 as the first closed-loop neuromodulation therapy for Parkinson's disease.
Expanding regulatory approvals and reimbursement support are increasing patient access, including Medtronic's September 2025 FDA approval of the Altaviva tibial neuromodulation system for urge urinary incontinence and LivaNova's November 2025 CMS reimbursement upgrade for VNS Therapy under the 2026 Medicare Hospital Outpatient Prospective Payment System.
Active strategic investment and M&A are consolidating and expanding neuromodulation capacity, including Boston Scientific's agreement to acquire Nalu Medical for approximately USD 533 million (announced October 2025) and Globus Medical's approximately USD 250 million acquisition of Nevro Corp. (announced February 2025).
Growing physician and patient preference for device-based, non-pharmacological alternatives to opioid therapy, combined with rising government funding for neuromodulation research, is broadening the addressable patient population across pain and neurological indications.
The convergence of technological innovation, expanding indications, rising disease burden, and reimbursement support is expected to sustain strong double-digit growth in the market through 2034.

Key Companies in Neuromodulation Devices Market

The competitive landscape is led by the following active device manufacturers:

Abbott Laboratories
Smith's Medical
B. Braun Melsungen AG
Baxter International Inc.
Boston Scientific Corp.
LivaNova PLC.
Medtronic
Nevro Corp.
Stryker

Factors Contributing to the Growth of the Neuromodulation Devices Market

Market Drivers

Rising Prevalence of Chronic Pain and Spinal Disorders

The most powerful driver of the Neuromodulation Devices market is the rising global prevalence of chronic pain, failed back surgery syndrome, and other refractory neuropathic conditions. Spinal cord stimulation delivers mild electrical pulses that interrupt pain signals before they reach the brain, reducing reliance on long-term opioid therapy and improving quality of life for patients who have not responded to conservative treatment. Manufacturers continue to differentiate on therapy precision and convenience: Nevro's HFX iQ platform applies an algorithm trained on tens of millions of data points drawn from more than 80,000 implanted patients, Medtronic's Inceptiv is among the thinnest implantable SCS devices available and senses the body's response to therapy fifty times per second, and Abbott's Proclaim Plus system with FlexBurst360 therapy extends coverage across up to six distinct pain areas. As national clinical guidelines increasingly recommend neuromodulation ahead of opioid escalation, demand for spinal cord stimulation capacity is expected to anchor market growth through 2034.

Growing Burden of Neurological and Movement Disorders

The expanding global burden of neurological and movement disorders, including Parkinson's disease, essential tremor, and drug-resistant epilepsy, is driving demand for deep brain and vagus nerve stimulation. The Parkinson's Foundation estimates that roughly 1 million people are living with Parkinson's disease in the United States, a number projected to rise to 1.2 million by 2030, while LivaNova's VNS Therapy remains a leading implantable option for patients with drug-resistant epilepsy who are unsuitable candidates for resective brain surgery. The completed CORE-VNS study, described as the largest real-world neuromodulation study for epilepsy, reported a median seizure reduction at 36 months of 80% for focal onset motor seizures with impaired awareness and 95% for focal-to-bilateral tonic-clonic seizures. As the treated population for movement and seizure disorders expands, demand for deep brain and vagus nerve stimulation devices rises correspondingly.

Market Restraints

Despite strong momentum, the Neuromodulation Devices market faces material constraints. Implantable neuromodulation systems and their associated surgical procedures carry high upfront costs, and reimbursement policy and coverage criteria vary considerably across geographies, which can slow adoption in price-sensitive and emerging markets. The invasive nature of many devices carries inherent surgical risks, including infection, lead migration, and hardware-related complications, while battery longevity, MRI-compatibility limitations, and the need for periodic device replacement add to long-term cost of care. A shortage of physicians trained in device implantation and programming constrains scale-up in several regions, and stringent regulatory pathways for implantable Class III devices lengthen development and approval timelines. Reimbursement and adoption of newer applications, including neuromodulation for depression, respiratory, and other emerging indications, remain uneven, and consolidation among a small number of large manufacturers concentrates competitive risk. Together, these cost, safety, regulatory, workforce, and reimbursement barriers temper the pace of growth, even as the underlying drivers of rising disease burden, technological innovation, and non-opioid demand remain firmly intact.

Neuromodulation Devices Market Segment Analysis

The Neuromodulation Devices by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Urinary & Faecal Incontinence, Neurological Disorders, Respiratory Disorders, and Others), Type (Invasive, Non-Invasive), End-Users (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

By Device Type

Dominant Subsegment: Spinal Cord Stimulators. The spinal cord stimulators category is expected to dominate the market.

Dominant: Small Molecule ~ 42%

The spinal cord stimulators segment accounted for 42% of the neuromodulation devices market in 2025. Spinal cord stimulators are the leading device type because chronic pain, particularly failed back surgery syndrome and other neuropathic pain conditions, affects a very large and growing patient population, and because SCS therapy is among the most clinically established and reimbursed neuromodulation modalities. Continuous product innovation, including rechargeable, closed-loop, and sensing-enabled systems from Medtronic, Abbott, Boston Scientific, and Nevro, has broadened patient eligibility and improved outcomes, while national clinical guidelines increasingly position SCS ahead of opioid escalation. Deep brain stimulators are expected to post the fastest growth of any device type over the forecast period, propelled by expanding indications in Parkinson's disease and essential tremor and by the commercial rollout of closed-loop adaptive DBS platforms, while sacral and vagus nerve stimulators continue to see steady adoption in incontinence and epilepsy care, respectively. Nonetheless, the scale, reimbursement maturity, and breadth of chronic pain indications addressed by spinal cord stimulation secure the segment's leadership across the forecast period.

By Application

Dominant Subsegment: Pain Management. The pain management category is expected to dominate the market.

Dominant: Pain Management ~ 47%

The pain management segment accounted for 47% of the Neuromodulation Devices market in 2025. Pain management leads all applications because chronic pain, including failed back surgery syndrome, complex regional pain syndrome, and painful diabetic neuropathy, affects a very large global population and is frequently refractory to pharmacological treatment, making device-based neuromodulation an increasingly preferred long-term therapy. Spinal cord, dorsal root ganglion, and peripheral nerve stimulation together address a broad range of chronic pain etiologies, and growing public health emphasis on reducing opioid dependence is reinforcing physician referral toward device-based options. Neurological disorders, spanning Parkinson's disease, essential tremor, and drug-resistant epilepsy, represent the fastest-growing application as adaptive DBS and next-generation VNS platforms expand treated populations, while urinary and faecal incontinence maintains steady demand through sacral and tibial neuromodulation, and respiratory disorder applications remain a smaller but emerging category. The sheer scale and clinical maturity of chronic pain indications secure pain management's leadership across the forecast period.

Neuromodulation Devices Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global neuromodulation devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high prevalence of chronic pain and neurological disorders, well-established reimbursement pathways through Medicare and private payers, deep clinical-research infrastructure, and the concentration of leading manufacturers including Medtronic, Abbott, Boston Scientific, and Nevro within the United States. Favorable reimbursement decisions, such as the 2025-2026 CMS payment classification upgrade for LivaNova's VNS Therapy and Medicare coverage support for spinal cord and sacral neuromodulation, continue to reinforce adoption. Heavy investment in next-generation adaptive DBS, AI-enabled SCS platforms, and peripheral nerve stimulation technology, combined with active M&A among leading device makers, sustains the region's leadership across the forecast period.

Dominant: North America ~ 44% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the neuromodulation devices market. The region's elevated growth is driven by rising prevalence of chronic pain and neurological disorders, expanding healthcare infrastructure and neurosurgical capacity, and growing government and private investment in advanced pain-management and neurology care across China, Japan, India, South Korea, and Australia. Japan continues to expand physician training and adoption of deep brain stimulation for movement disorders, China is scaling neurosurgical and pain-management infrastructure, and India offers a large and underserved patient population alongside improving access to specialty care. Rising disposable incomes, growing insurance penetration, and increasing awareness of device-based alternatives to long-term pharmacological pain management are accelerating regional adoption, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Neuromodulation Devices market revenue in 2025. The United States dominates on the strength of its reimbursement infrastructure, dense concentration of leading manufacturers, and deep clinical-research base, while ongoing FDA approvals for adaptive DBS, tibial and sacral neuromodulation, and peripheral nerve stimulation reinforce the region's leadership.

Europe

Europe is a large and technologically advanced regional market, supported by established CE Mark and national reimbursement frameworks, a strong base of neurosurgical and pain-management centers, and active clinical evidence generation. Regional manufacturing and clinical partnerships across Germany, the United Kingdom, France, Italy, and Spain support both diagnostic assessment and long-term management of chronic pain and neurological disorders.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising chronic pain and neurological disease burden, expanding neurosurgical and pain-management infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Physician training programs and improving reimbursement access are accelerating regional adoption of spinal cord and deep brain stimulation.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare infrastructure, rising awareness of neuromodulation as an alternative to long-term pharmacological pain management, and gradually improving access to specialty neurosurgical and pain-management care are broadening adoption, while international partnerships support training and technology transfer.

Neuromodulation Devices Market Competitive Landscape

The Neuromodulation Devices market is classified as Moderately Concentrated. A group of large, diversified medical technology companies with deep neuromodulation portfolios, including Medtronic, Abbott Laboratories, Boston Scientific Corp., and LivaNova PLC, anchor the top tier through broad device-type coverage, established reimbursement relationships, and global commercial reach, while focused specialists such as Nevro Corp. compete through differentiated spinal cord stimulation technology and continued clinical evidence generation. Diversified medical technology companies including Baxter International Inc., B. Braun Melsungen AG, Smith's Medical, and Stryker participate through adjacent interventional pain, infusion, and surgical technology portfolios that support the broader chronic-pain and neurological-care ecosystem in which neuromodulation devices are used.

The competitive landscape can be evaluated across the following dimensions:

Market concentration: Moderately concentrated, with large diversified device makers leading and a smaller field of focused neuromodulation specialists.
Leading players: Medtronic, Abbott Laboratories, Boston Scientific Corp., and LivaNova PLC. anchor the top tier through broad device portfolios and global commercial infrastructure.
Geographic reach: Leaders operate global commercial and clinical-support networks spanning North America, Europe, and expanding Asia-Pacific operations.
Portfolio strength: Top players offer end-to-end neuromodulation portfolios spanning spinal cord, deep brain, sacral, and vagus nerve stimulation alongside supporting digital health platforms.
Technology innovation: Closed-loop, sensing-enabled, and AI-driven platforms, including Medtronic's BrainSense Adaptive DBS and Nevro's HFX iQ with HFX AdaptivAI, are a decisive competitive advantage.
Strategic partnerships and M&A: Active consolidation, including Boston Scientific's agreement to acquire Nalu Medical and Globus Medical's acquisition of Nevro Corp., is reshaping competitive share.
Regulatory and reimbursement depth: Proven approval track records and payer relationships, exemplified by LivaNova's CMS reimbursement upgrade for VNS Therapy, are a key barrier to entry.
Manufacturing capabilities: Precision electronics manufacturing, implantable-grade battery technology, and biocompatible lead design are key competitive moats.
Innovation focus: Closed-loop and AI-enabled stimulation, miniaturization, MRI-conditional labeling, and expansion into peripheral nerve stimulation and new indications.

Neuromodulation Devices Market Recent Developmental Activities

In January 2026, Boston Scientific Corp. progressed toward completing its previously announced acquisition of Nalu Medical, expanding its neuromodulation portfolio into peripheral nerve stimulation for chronic pain. Strategic significance: Broadens Boston Scientific's chronic-pain portfolio beyond spinal cord stimulation into peripheral nerve stimulation.

In November 2025, LivaNova PLC announced that the U.S. Centers for Medicare & Medicaid Services assigned VNS Therapy to an upgraded New Technology Ambulatory Payment Classification, effective January 2026, improving hospital procedure economics. Strategic significance: Broadens patient access to VNS Therapy and strengthens LivaNova's reimbursement position in drug-resistant epilepsy.

Neuromodulation Devices Market Segmentation

Neuromodulation Devices Market by Device Type

Spinal Cord Stimulators
Deep Brain Stimulators
Sacral Nerve Stimulators
Vagus Nerve Stimulators
Others

Neuromodulation Devices Market by Application

Pain Management
Urinary & Faecal Incontinence
Neurological Disorders
Respiratory Disorders
Others

Neuromodulation Devices Market by Type

Invasive
Non-Invasive

Neuromodulation Devices Market by End-Users

Hospitals
Specialty Clinics
Others

Neuromodulation Devices Market by Geography

North America Neuromodulation Devices Market
United States Neuromodulation Devices Market Size in USD million (2023-2034)
Canada Neuromodulation Devices Market Size in USD million (2023-2034)
Mexico Neuromodulation Devices Market Size in USD million (2023-2034)
Europe Neuromodulation Devices Market
Germany Neuromodulation Devices Market Size in USD million (2023-2034)
United Kingdom Neuromodulation Devices Market Size in USD million (2023-2034)
France Neuromodulation Devices Market Size in USD million (2023-2034)
Italy Neuromodulation Devices Market Size in USD million (2023-2034)
Spain Neuromodulation Devices Market Size in USD million (2023-2034)
Rest of Europe Neuromodulation Devices Market Size in USD million (2023-2034)
Asia-Pacific Neuromodulation Devices Market
China Neuromodulation Devices Market Size in USD million (2023-2034)
Japan Neuromodulation Devices Market Size in USD million (2023-2034)
India Neuromodulation Devices Market Size in USD million (2023-2034)
Australia Neuromodulation Devices Market Size in USD million (2023-2034)
South Korea Neuromodulation Devices Market Size in USD million (2023-2034)
Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2023-2034)
Rest of the World (RoW) Neuromodulation Devices Market
Middle East Neuromodulation Devices Market Size in USD million (2023-2034)
Africa Neuromodulation Devices Market Size in USD million (2023-2034)
South America Neuromodulation Devices Market Size in USD million (2023-2034)

Key Takeaways from the Neuromodulation Devices Market Report Study

Market size analysis for the current neuromodulation devices market size (2025), and market forecast for 9 years (2026 to 2034).
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
Key companies dominating the global neuromodulation devices market.
Various opportunities available for competitors in the neuromodulation devices market space.
What are the top-performing segments in 2025? How will these segments perform in 2034?
Which are the top-performing regions and countries in the current neuromodulation devices market scenario?
Which are the regions and countries where companies should concentrate their opportunities for neuromodulation devices market growth in the future?

Target audience who can benefit from this neuromodulation devices market report study

Neuromodulation devices product providers
Research organizations and consulting companies
Neuromodulation devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in neuromodulation devices
Various end-users who want to know more about the neuromodulation devices market and the latest technological developments in the neuromodulation devices market.

Frequently Asked Questions:

Q1. What is the growth rate of the neuromodulation devices market?

The neuromodulation devices market is projected to expand at a CAGR of 10.6% during the forecast period from 2026-2034.

Q2. What is the market size of the neuromodulation devices market?

The neuromodulation devices market is estimated at USD 6.42 billion in 2025 and is projected to reach USD 15.85 billion by 2034.

Q3. Which region dominates the neuromodulation devices market?

North America dominated the neuromodulation devices market with a 44% share of global revenue in 2025, supported by a high prevalence of chronic pain and neurological disorders, well-established reimbursement pathways, and the concentration of leading manufacturers within the United States. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the neuromodulation devices market?

The principal drivers are the rising global prevalence of chronic pain and failed back surgery syndrome; the growing burden of neurological and movement disorders, including Parkinson's disease and drug-resistant epilepsy; rapid advancement toward closed-loop and AI-enabled stimulation platforms; expanding regulatory approvals and reimbursement support; and active strategic investment and M&A activity among leading manufacturers.

Q5. Who are the major players in the neuromodulation devices market?

The major players include Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC, Medtronic, Nevro Corp., and Stryker, among others.

1. Neuromodulation Devices Market Report Introduction

1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. Neuromodulation Devices Market Executive Summary

2.1 Market at a Glance

3. Neuromodulation Devices Market Key Factors Analysis

3.1 Neuromodulation Devices Market Drivers
- 3.1.1 Rising Prevalence of Chronic Pain and Spinal Disorders
- 3.1.2 Growing Burden of Neurological and Movement Disorders
- 3.1.3 Technological Advancement Toward Closed-Loop and AI-Enabled Stimulation
- 3.1.4 Expanding Regulatory Approvals and Reimbursement Support
3.2 Neuromodulation Devices Market Restraints and Challenges
- 3.2.1 High Device and Procedure Costs
- 3.2.2 Surgical Risks and Reimbursement Variability
- 3.2.3 Regulatory Complexity and Workforce Constraints
3.3 Neuromodulation Devices Market Opportunities
- 3.3.1 Closed-Loop and AI-Enabled Platform Expansion
- 3.3.2 Emerging-Market and New-Indication Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. Neuromodulation Devices Market Porter's Five Forces Analysis

6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. Neuromodulation Devices Market Assessment

7.1 By Device Type
- 7.1.1 Spinal Cord Stimulators
- 7.1.2 Deep Brain Stimulators
- 7.1.3 Sacral Nerve Stimulators
- 7.1.4 Vagus Nerve Stimulators
- 7.1.5 Others
7.2 By Application
- 7.2.1 Pain Management
- 7.2.2 Urinary & Faecal Incontinence
- 7.2.3 Neurological Disorders
- 7.2.4 Respiratory Disorders
- 7.2.5 Others
7.3 By Type
- 7.3.1 Invasive
- 7.3.2 Non-Invasive
7.4 By End-Users
- 7.4.1 Hospitals
- 7.4.2 Specialty Clinics
- 7.4.3 Others
7.5 By Geography
- 7.5.1 North America
  - 7.5.1.1 United States Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.1.2 Canada Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.1.3 Mexico Neuromodulation Devices Market Size in USD million (2023-2034)
- 7.5.2 Europe
  - 7.5.2.1 Germany Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.2.2 United Kingdom Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.2.3 France Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.2.4 Italy Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.2.5 Spain Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.2.6 Rest of Europe Neuromodulation Devices Market Size in USD million (2023-2034)
- 7.5.3 Asia-Pacific
  - 7.5.3.1 China Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.3.2 Japan Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.3.3 India Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.3.4 Australia Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.3.5 South Korea Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.3.6 Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2023-2034)
- 7.4.4 Rest of World
  - 7.5.4.1 Middle East Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.4.2 Africa Neuromodulation Devices Market Size in USD million (2023-2034)
  - 7.5.4.3 South America Neuromodulation Devices Market Size in USD million (2023-2034)

8. Neuromodulation Devices Market Competitive Landscape

8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Neuromodulation Devices Market Startup Funding and Investment Trends

10. Neuromodulation Devices Market Company and Product Profiles

10.1 Abbott Laboratories
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
10.2 Smith's Medical
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
10.3 B. Braun Melsungen AG
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
10.4 Baxter International Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
10.5 Boston Scientific Corp
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
10.6 LivaNova PLC.
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
10.7 Medtronic
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
10.8 Nevro Corp.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
10.9 Stryker
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10.10 Omron Corporation
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.